Table 4. Factors associated with the development of hepatocellular carcinoma (HCC) in over 6-month or 1-year follow up model.
| Category | Cut off | Univariate | Multivariate (after 6 month, n = 1245) | Multivariate (after 1 year, n = 1195) | ||||
|---|---|---|---|---|---|---|---|---|
| P value | P value | Hazard Ratio | 95%CI | P value | Hazard Ratio | 95%CI | ||
| Age | ≥73 years | 0.001 | 0.045 | 1.782 | 1.014–3.132 | 0.057 | 1.816 | 0.983–3.355 |
| Sex | Male | <0.001 | <0.001 | 2.835 | 1.605–5.007 | <0.001 | 3.088 | 1.652–5.772 |
| Etiology | Cirrhosis present | <0.001 | ||||||
| Prior DAA therapy | DAA experience | 0.574 | ||||||
| Platelet counts | <11.3×104 /μL | <0.001 | ||||||
| Total bilirubin | ≥0.8 mg/dL | 0.006 | ||||||
| AST | ≥47 U/L | <0.001 | ||||||
| ALT | ≥36 U/L | 0.078 | ||||||
| GGT | ≥31 U/L | 0.006 | ||||||
| Alb | <3.9 g/dL | <0.001 | 0.019 | 2.084 | 1.127–3.856 | |||
| Hyaluronic acid | ≥75 ng/mL | <0.001 | 0.007 | 3.481 | 1.411–8.583 | 0.009 | 3.300 | 1.343–8.105 |
| Fib-4 index | ≥4.03 | <0.001 | ||||||
| AFP | ≥7.1 ng/mL | <0.001 | ||||||
| EOT-ALT | Not WNL | 0.070 | ||||||
| EOT-Alb | <3.9 g/dL | <0.001 | 0.007 | 2.289 | 1.218–4.303 | |||
| EOT-AFP | ≥5.3 ng/mL | <0.001 | <0.001 | 4.257 | 2.352–7.704 | <0.001 | 3.288 | 1.754–6.163 |
95%CI, 95% confidence interval; DAA, direct-acting antivirals; AST, aspartate transaminase; ALT, alanine transaminase; GGT, γ-glutamyltransferase; Alb, albumin; AFP, α-fetoprotein; EOT, end of treatment; WNL, within normal limit.